Thrombosis Research (2005) **116**, 545–550

ELSEVIER

THROMBOSIS RESEARCH

intl.elsevierhealth.com/journals/thre

Author Index—Volumes 115-116 (2005)

Abaci, A., **116**:465
Abe, Y., **115**:271; **116**:307
Abeyama, K., **115**:319
Abildgaard, U., **115**:519
Abrahamsson, T.I., **116**:519
Ageno, W., **116**:301
Agnelli, G., **116**:301
Agnese, A.M., **115**:494
Ahmed, R.P.H., **115**:535
Aizawa, Y., **115**:219
Akar, N., **115**:159, 393
Akin, M., **116**:287
Aksu, K., **115**:287
Al Yemeni, E., **116**:377
Alfonso, F., **115**:101; **116**:491
Almanric, K., **116**:41
Almsherqi, Z.A., **116**:451
Altieri, P., **115**:65
Alves-Filho, J.C.F., **115**:537
Amato, S., **116**:443
Ambrosio, G.B., **116**:301
Ammannati, F., **115**:405
Anand, S., **115**:491
Andresen, M.S., **115**:519
Angiolillo, D.J., **115**:101; **116**:491
Antovic, A., **116**:509
Aoki, N., **116**:455
Aoyagi, K., **115**:271
Arnesen, H., **115**:163, 257; **116**:313
Astermark, J., **116**:15
Atalay, F., **115**:159
Aurigemma, C., **116**:25
Ayaz, S., **115**:25
Aydin, H.H., **115**:287
Aznar, J., **115**:263, 399; **116**:447

Bach, J., **116**:33
Badar, J., **116**:55
Bae, O.-N., **116**:157
Bai, X., **116**:385
Baier, K., **115**:135
Balbay, Y., **115**:25
Balbi, M., **115**:65
Bang, N.U., **115**:73
Bañuelos, C., **115**:101; **116**:491
Barnes, T.A., **115**:461
Barrera-Ramirez, C., **115**:101
Barsotti, A., **115**:65
Bartok, A., **115**:469
Baskin, E., **115**:185
Bass, T.A., **115**:101; **116**:491
Bayram, F., **116**:465
Baz-Hecht, M., **116**:1
Bazinet, A., **116**:41
Bazzan, M., **116**:301
Beaulieu, E., **115**:143
Bégaud, B., **115**:31
Beight, D.W., **116**:265
Béliveau, R., **115**:143
Bene, J., **116**:479
Berdeli, A., **116**:287
Berggren, M., **116**:249
Berloco, P., **116**:471
Bernardo, E., **115**:101; **116**:491
Berntorp, E., **116**:15
Bersi, C., **116**:207
Bertero, G., **115**:65
Bertoldi, A., **116**:301
Bertsch, T., **116**:171
Bhattacharya, M., **115**:534
Biswas, A., **115**:535
Björkman, J.-A.E., **116**:519
Bjørn, S.E., **116**:75
Blais, N., **116**:41
Blann, A.D., **115**:205; **116**:181, 377
Blessing, F.J., **115**:39
Bliden, K.P., **115**:89
Blombäck, M., **116**:509
Boehlen, F., **115**:131
Boisseau, M., **115**:31
Boivin, D., **115**:143
Boman, K., **116**:249
Boneu, B., **116**:293
Bordet, J.C., **116**:483
Borensztajn, K., **116**:115
Branner, S., **116**:75
Brennan, S.O., **115**:293
Brenner, B., **116**:109
Broberg, A., **116**:249
Broekman, M.J., **116**:199
Brunelli, C., **115**:65
Brunet, C., **116**:41
Bruno, A., **115**:73
Budihna, M.V., **115**:527

Cabrera, J.L., **115**:495
Cadroy, Y., **116**:293
Cagirgan, S., **115**:287
Caldir, V., **115**:25
Calevo, M.G., **116**:443
Caliskan, M., **116**:465
Calvo, J., **115**:399
Cam, S.F., **116**:287
Carlsson, S.C., **115**:9
Carmassi, F., **116**:207
Caron, S., **116**:41
Carroll, R.C., **116**:51
Cavallari, U., **116**:491
Celik, H.A., **115**:287
Cengiz, N., **115**:185
Cerbone, A.M., **115**:439
Černe, M., **115**:526
Cetin, M., **116**:465
Cetin, S., **116**:465
Chafa, O., **116**:115
Chandler, W.L., **115**:327
Chang, G.-T., **116**:421

0049-3848/$ - see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/S0049-3848(05)00386-5

Chang, T.-S., **115**:309
Chen, C., **115**:417
Chen, C.-Y., **115**:153
Chesebro, J.H., **116**:525
Chiang, T.M., **115**:503
Chin, B.S.P., **116**:181
Choi, E.-Y., **116**:421
Chong, A.Y., **116**:181
Christensen, J.H., **115**:257
Christensen, K., **115**:245
Chung, I., **116**:275
Chung, J.-H., **115**:309; **116**:157
Chung, K.-H., **116**:421
Chung, K.-Y., **116**:157
Chung, S.-M., **116**:157
Cirillo, F., **115**:439
Cohen, S.N., **115**:73
Colucci, M., **116**:471
Contreras, M.T., **115**:399
Cooley, B.C., **115**:153
Coppola, A., **115**:439
Corella, D., **115**:399
Cosman, F., **116**:1
Costa, M.A., **115**:101; **116**:491
Covic, L., **116**:55
Crea, F., **116**:25
Crowther, M.A., **115**:3
Cruz, J.D., **116**:1
Cullinane, A.M., **116**:499
Cushman, M., **116**:1
Cvirn, G., **115**:135

Dally, N., **116**:109
Dampier, K., **115**:461
Dargaud, Y., **116**:483
Datta, Y., **115**:153
De Boer, R.A., **116**:279
De Caterina, R., **115**:163, 257
De Faire, U., **116**:223
De Giorgi, A., **116**:207
De Moerloose, P., **115**:131
De Negri, F., **116**:207
De Simone, C., **115**:439
Dechavanne, M., **116**:483
Deda, G., **115**:393
DeLa Cadena, R.A., **116**:533
Dell'Omo, G., **116**:207
Dempfle, C.-E., **116**:171
Deng, G., **115**:341
Deng, Y., **116**:451
Denis Alexander, H., **115**:109
Deol, P.S., **115**:461
Depont, F., **115**:31
Devoto, E., **115**:65
Di Leo, A., **116**:471
Do, Y.H., **116**:265
Doganavsargil, E., **115**:287
Dogné, J.-M., **116**:431
Dole, W.P., **115**:341
Donmez, A., **115**:287
D'Orio, V., **116**:431
Dorn-Beineke, A., **116**:171
Drevenšek, G., **115**:526
Drion, P., **116**:431
Drosopoulos, J.H.F., **116**:199

Ekman, G.J., **116**:509
Elder, R.F., **116**:51
Elgue, G., **115**:245
Elhan, A.H., **115**:393
Eliasson, Å., **115**:9
Elm, T., **116**:75
El-Omar, M.M., **116**:199
Emanuelsson, H., **115**:245
Emi, Y., **116**:215
Endo, S., **116**:357
Ercan, E., **116**:287
Eriksson, U.G., **115**:9
Ernam, D., **115**:159
Escaned, J., **115**:101, **116**:491
España, F., **115**:399

Fattal-Valevski, A., **116**:133
Fernandez-Ortiz, A., **115**:101; **116**:491
Ferrando, F., **116**:447
Fioriti, R., **116**:207
Fischer, A.-M., **116**:115
Fischer, J.E., **115**:175
Fischler, B., **116**:185
Fisher, M., **115**:435
For the Warfarin Optimal Duration Italian Trial (WODIT) Investigators, **116**:301
Forslund, M., **116**:241
Francis, C., **115**:1
Frederick, M., **115**:327
Friedman, K.D., **115**:153
Fruzzetti, F., **116**:207
Fujikawa, K., **115**:441
Funahashi, T., **115**:483
Fuse, I., **115**:219

Gabriel, F., **115**:263
Gallistl, S., **115**:135
Gando, S., **116**:91
García-Herola, A., **116**:321
Garibaldi, S., **115**:65
Gasztonyi, B., **116**:479
Geisen, C., **115**:534
Gende, O.A., **116**:67
George, P.M., **115**:293
Gerrits, W.B.J., **115**:381
Ghigliotti, G., **115**:65
Ghuysen, A., **116**:431
Giannarelli, C., **116**:207
Giddings, J.C., **116**:393
Gifford-Moore, D.S., **116**:265
Gilmore, W.S., **115**:109
Gingras, D., **115**:143
Ginsberg, J., **115**:1
Glazier, G., **115**:143
Goldenberg, N.A., **116**:345
Golding, B., **116**:335
Gorelick, P.B., **115**:73
Grabowski, E.F., **116**:409
Granlund, A., **116**:249
Grill, D.E., **116**:525
Guazzaloca, G., **116**:301
Guglielmone, H.A., **115**:495
Guiral, V., **115**:263
Gumulec, J., **115**:427
Guray, U., **115**:25
Guray, Y., **115**:25
Gurbel, P.A., **115**:89

Haddad, N., **116**:109
Hallqvist, J., **116**:223
Hamasaki, N., **115**:351
Hanson, J., **116**:431
Hanson, S.R., **115**:79
Harel, S., **116**:133
Harish Kumar, M., **116**:255
Hashiguchi, T., **115**:319
Hashimoto, N., **116**:215
Hassinger, N.L., **116**:525
Hassner, A., **116**:133
Hathaway, W.E., **116**:345
Havasi, V., **116**:479
Hayakawa, M., **116**:91
Hayakawa, Y., **116**:357
Hayashi, N., **116**:357
He, S., **116**:509
Held, P., **115**:9
Hellstern, P., **116**:33
Hemker, H.C., **115**:255
Hennessey, M.D., **116**:51
Heptinstall, S., **115**:301
Hernández, R., **115**:101; **116**:491
Hillbom, M., **115**:367
Hillege, H.L., **116**:279
Hiller, E., **116**:233
Hirashima, Y., **116**:357
Hirokawa, T., **115**:475
Hjemdahl, P., **116**:509
Hjerkinn, E.M., **116**:313
Hoffman, R., **116**:109

Hokamaki, J., **115**:483
Honda, O., **115**:483
Horne III, M.K., **116**:499
Hoshino, H., **116**:91
Howley, H.E.A., **116**:101
Hu, H., **116**:241
Huang, H.-Y., **116**:145
Huber, K., **115**:469
Hudig, F., **115**:381
Hursting, M.J., **116**:121
Huwer, H., **116**:33

Ichikawa, S., **115**:359
Iida, H., **115**:351
Ijiri, Y., **115**:115
Ijiru, Y., **116**:393
Ikarugi, H., **116**:127, 403
Ikeda, T., **116**:215
Ikeda, Y., **115**:191
Imanaka, T., **116**:215
Imberti, D., **116**:365
Inal, V., **115**:287
Infusino, F., **116**:25
Ingelfinger, J.R., **116**:409
Inman, J., **116**:335
Inoue, A., **116**:127, 403
Inoue, S., **115**:351
Ishii, H., **116**:127, 403
Ishii, K., **115**:191
Ishikura, K., **115**:53; **116**:307
Isik Agras, P., **115**:185
Islam, N., **116**:199
Isordia-Salas, I., **116**:533
Iwamoto, H., **115**:319
Iwasaka, T., **115**:277
Iwata, M., **115**:211

Jacobson, A., **115**:45
Jacobson, L., **116**:345
Jacques, S., **116**:55
Jacquet, A., **115**:31
Jaeger, B., **115**:39
Jäger, U., **115**:59
Jansen, R.W., **115**:381
Jansson, J.-H., **116**:249
Jetzl, A., **115**:469
Ji, S., **116**:385
Jiang, M., **116**:385
Jimenez-Quevedo, P., **116**:491
Johnston, M., **115**:427
Jones, S.W., **115**:341
Juvela, S., **115**:367

Kalnoski, M.H., **115**:327
Kalweit, G., **116**:33
Kameue, T., **116**:91
Kamikura, Y., **115**:53; **116**:307
Kang, H.-M., **115**:327
Kannan, M., **115**:534
Karahan, Z.C., **115**:393
Karalis, I., **116**:377
Kario, K., **115**:475
Karlson, B.W., **115**:9
Katayama, K., **116**:215
Katayama, M., **116**:215
Kathriner, S., **116**:165
Kato, H., **116**:91
Katori, N., **115**:79
Kavlie, A., **116**:313
Kawano, H., **115**:483
Kazahaya, Y., **115**:53
Kelly, A.B., **115**:79
Kelton, J.G., **116**:121
Kenet, G., **116**:133
Kerényi, A., **116**:139
Keser, G., **115**:287
Khil, L.-Y., **115**:309
Kim, C.-H., **116**:421
Kim, D., **115**:309
Kim, J.A., **115**:435
Kim, J.-H., **116**:421
Kim, Y.-C., **115**:309
Kimmelstiel, C., **116**:55
Kinoshita, S., **115**:351
Kirazli, S., **115**:185
Kirszberg, C., **115**:123
Kitagawa, A., **115**:483
Kitajima, I., **116**:215
Kitamari, K., **116**:127
Klement, P., **115**:427
Kliber, A., **115**:491
Klimkowski, V.J., **116**:265
Knöbl, P., **115**:59
Kobayashi, T., **116**:307
Koestenberger, M., **115**:135
Kojima, S., **115**:483
Kolb, H.J., **116**:233
Kolh, P., **116**:431
Komlósi, K., **116**:479
Kono, M., **115**:271
Kopp, C.W., **115**:469
Korkmaz, S., **115**:25
Koschinsky, M.L., **115**:491
Kotze, H., **115**:79
Krishna Biswas, K., **115**:319
Kristensen, S.D., **115**:163, 257
Kroner, C., **116**:327
Kudielka, B.M., **115**:175
Kuliopulos, A., **116**:55
Kumakura, H., **115**:359
Kupferminc, M.J., **116**:133
Kurabayashi, M., **115**:359
Kurihara, M., **115**:351
Kurimoto, M., **116**:357
Kushak, R.I., **116**:409
Kuwayama, N., **116**:357

Labiós, M., **115**:263
Lalonde, L., **116**:41
Lamassa, M., **115**:405
Lambermont, B., **116**:431
Lambert, J., **116**:409
Lane, J.R., **115**:45
Lanza, G.A., **116**:25
Larosa, C., **116**:25
Larsson, A., **115**:245
Larsson, R., **115**:245
Le Bonniec, B., **116**:115
Leander, K., **116**:223
Lechner, K., **115**:59
Lee, B.-H., **115**:309
Lee, G.-Y., **115**:309
Lee, K.-S., **115**:309
Lee, M.-Y., **116**:157
Lee, S.-J., **116**:157
Lehr, S., **115**:59
Leitner, Y., **116**:133
Leschnik, B., **115**:135
Lethagen, S., **116**:15
Lewis, B.E., **116**:121
Li, N., **116**:241
Liang, A., **115**:341
Liestøl, S., **115**:509
Lignot, S., **115**:31
Lin, P., **115**:417
Lindman, A.S., **116**:313
Lindsay, R., **116**:1
Lip, G.Y.H., **115**:171, 205; **116**:181, 275, 321, 377
Liu, C.-Z., **116**:145
Liu, Y., **115**:319
Lorin, J.D., **116**:199
Lu, D., **116**:265
Lumsden, A.B., **115**:417

Macaya, C., **115**:101; **116**:491
Maccallini, A., **116**:25
MacFadyen, R.J., **115**:205
Maghzal, G.J., **115**:293
Magis, D., **116**:431
Makris, M., **115**:451
Małyszko, J., **115**:19
Małyszko, J.S., **115**:19
Manco-Johnson, M.J., **116**:345
Manns, J.M., **116**:533
Marcus, A.J., **116**:199
Marín, F., **116**:321
Mariotti, F., **115**:405

Marroni, A.S., **115**:375
Marsh, J.J., **115**:45
Martineau, J., **116**:41
Martínez, E., **115**:263
Martínez, M., **115**:263
Maruyama, I., **115**:319
Maruyama, M., **116**:255
Maruyoshi, H., **115**:483
Marzec, U., **115**:79
Maser, E., **116**:101
Masereel, B., **116**:431
Matsuda, M., **115**:53
Matsuda, N., **116**:91
Matsumoto, T., **115**:53
Matsuo, T., **115**:475
Matsuzawa, Y., **115**:483
Matthai Jr., W.H., **116**:121
Mattsson, C., **115**:9
Mattsson, C.J., **116**:519
May, J.A., **115**:301
Mazet, M., **116**:483
McBane II, R.D., **116**:525
McConnell, J.P., **115**:73
McGlynn, H., **115**:109
Mclachlan, C., **116**:451
Melegh, B., **116**:479
Melegh, G., **116**:479
Mello, G., **115**:405
Mennonna, P., **115**:405
Merchlinsky, M., **116**:335
Merryman, P.K., **116**:499
Mesterman, R., **116**:133
Metzger, I.F., **115**:375
Miall, F.M., **115**:461
Middeldorp, J.M., **115**:387
Minar, E., **115**:469
Minematsu, K., **115**:455
Mira, Y., **116**:447
Mischke, R., **115**:229
Mischler, K., **115**:175
Miyamoto, S., **115**:483
Moia, M., **116**:301
Molinari, A.C., **116**:443
Monteiro, R.Q., **115**:123
Moon, C.-H., **115**:309
Moon, C.-K., **115**:309
Moore, N., **115**:31
Moreno, R., **115**:101; **116**:491
Moreno-Aspitia, A., **116**:87
Moriki, T., **115**:191
Morris, T.A., **115**:45
Morser, J., **115**:341
Mossop, P.J., **116**:451
Mózsik, G., **116**:479
Mruk, J.S., **116**:525
Muenchen, R.A., **116**:51
Muntean, W., **115**:135
Muradin, A.A., **115**:381
Murata, M., **115**:191
Muszbek, L., **116**:139
Myśliwiec, M., **115**:19

Nadar, S.K., **116**:377
Nádasi, E., **116**:479
Naemura, A., **115**:115
Nagassaki, S., **115**:375
Nakamura, T., **115**:211
Nakano, T., **115**:53, 211, **116**:215, 307
Nan, B., **115**:417
Naritomi, H., **115**:455
Negrier, C., **116**:483
Nemeth, A., **116**:185
Nerme, V.K., **116**:519
Nestoridi, E., **116**:409
Nieves, D.R., **115**:1
Nieves, J.W., **116**:1
Nilsson, G., **116**:15
Nilsson, T.K., **116**:249
Nishiguchi, M., **115**:271
Nishikawa, M., **115**:277; **116**:307
Nishioka, J., **116**:307
Niwano, H., **115**:219
Nobori, T., **115**:53; **116**:307
Nomura, S., **115**:277; **116**:215
Nørby, P.L., **116**:75
Nordenhem, A., **116**:223
Núñez Montoya, S.C., **115**:494

Oda, E., **115**:115, **116**:393
Ogawa, H., **115**:483
Oguchi, S., **115**:191
Oh, J.-Y., **116**:421
Ohmori, T., **115**:409
Okada, Y., **116**:403
Ökten, F., **115**:159
Oldenburg, J., **115**:534
Olson, K.E., **116**:199
Olwill, S.A., **115**:109
Omay, S.B., **115**:287
Omoto, S., **115**:277
Omura, S., **116**:255
On behalf of HIT Research Group of Japan, **115**:475
Ono, M., **115**:351
Oppenheimer, C.A., **115**:461
Osada, M., **115**:409
Owers, R.L., **116**:51
Ozaki, Y., **115**:409
Ozawa, T., **116**:215
Ozbek, N., **115**:185
Palmieri, N.M., **115**:439
Papp, E., **116**:479
Parekh, H., **116**:533
Parretti, E., **115**:405
Pasi, K.J., **115**:461
Patteson, S.K., **116**:51
Pavord, S.R., **115**:461
Pchelina, S.N., **115**:199
Pedersen, J.I., **116**:313
Pedrinelli, R., **116**:207
Peng, L., **115**:427
Penovici, M., **116**:233
Pentimone, A., **116**:471
Perneby, C., **116**:509
Persson, E., **116**:75
Perutelli, P., **116**:443
Pétein, M., **116**:431
Peternel, L., **115**:527
Petersen, L.C., **116**:75
Petrini, P., **116**:185
Pettersson, M., **116**:185
Pignatti, P.F., **116**:491
Pihusch, M., **116**:233
Pihusch, R., **116**:233
Pihusch, V., **116**:233
Pirotte, B., **116**:431
Prandoni, P., **116**:301
Preckel, D., **115**:175
Prisco, D., **116**:365
Provençal, M., **115**:143
Pulte, E.D., **116**:199
Pyhtinen, J., **115**:367

Radha, K.S., **116**:255
Rak, J., **115**:427
Ramírez, C., **115**:101; **116**:491
Rasmussen, L.H., **115**:163, 257
Ratel, D., **115**:143
Rathnachalam, R., **116**:265
Reber, G., **115**:131
Rechner, A.R., **116**:327
Reghis, A., **116**:115
Ricart, J.M., **115**:399
Richardson, D., **115**:73
Rimon, E., **116**:133
Riutta, A., **115**:367
Riviello, C., **115**:405
Roa, D.C., **116**:199
Rodger, M.A., **116**:101
Roldán, V., **116**:321
Rolin, S., **116**:431
Rosendaal, F.R., **115**:387
Ross, C.M., **116**:273
Rossettin, P., **115**:65
Rossiello, M.R., **116**:471

Rowe, J.M., **116**:109
Ruan, C., **116**:385
Rumjanek, V.M., **115**:123
Russo, F., **116**:471
Rutten, W.P.F., **115**:239

Saatci, U., **115**:185
Sabaté, M., **115**:101; **116**:491
Sagcan, A., **116**:287
Sainz, I., **116**:533
Sakamaki, T., **115**:359
Sakamoto, H., **115**:359
Sakamoto, T., **115**:483
Sakariassen, K., **116**:293
Sakata, T., **115**:455
Saloheimo, P., **115**:367
Samara, W.M., **115**:89
Sándor, J., **116**:479
Sandset, P.R., **115**:1
Sano, T., **115**:115; **116**:393
Santamaria, M.G., **116**:301
Sarich, T.C., **115**:9
Sarig, G., **116**:109
Sase, T., **116**:307
Sato, A., **116**:127
Sato, N., **115**:219
Sawada, Y., **115**:359
Sawai, T., **115**:53
Saxena, R., **115**:535
Scherjon, S.A., **115**:387
Schmidt, E.B., **115**:163, 257
Schoon, H.-A., **115**:229
Schulman, S., **116**:185
Schwartz, E.I., **115**:199
Sedlis, S.P., **116**:199
Segers, P., **116**:431
Segur, M.C., **115**:31
Seidel, D., **115**:39
Seidinger, D., **115**:469
Seifried, E., **115**:534
Seki, Y., **115**:219
Sekuri, C., **116**:287
Selig, M.K., **116**:409
Seljeflot, I., **116**:313
Semeraro, N., **116**:471
Sestito, A., **116**:25
Sgueglia, G.A., **116**:25
Shah, A.K., **116**:87
Sheth, S.B., **115**:9
Shih, M.-H., **116**:145
Shiku, H., **115**:53, **116**:307
Shindo, H., **115**:271
Shouzu, A., **115**:277
Shwarzman, A.L., **115**:199
Silingardi, M., **116**:301
Sipahi, T., **115**:393
Sirotkina, O.V., **115**:199
Snider, C.C., **116**:51
Snider, R.M., **115**:341
Soejima, H., **115**:483
Soltész, P., **116**:139
Sørensen, B.B., **116**:75
Souza-Costa, D.C., **115**:375
Spallarossa, P., **115**:65
Sperr, W.R., **115**:59
Štalc, A., **115**:526
Stefenelli, T., **115**:469
Stegnar, M., **115**:526
Steiner, S., **115**:469
Sten-Linder, M., **116**:223
Stennicke, H.R., **116**:75
Stiell, I., **116**:101
Storey, R.F., **115**:301
Sugiki, M., **116**:255
Sugiyama, S., **115**:483
Sumino, H., **115**:359
Szegedi, G., **116**:139
Szolnoki, Z., **116**:479

Takahashi, H., **115**:219
Takamura, N., **115**:271
Takayama, Y., **115**:359
Takeshita, E., **115**:191
Talián, G., **116**:479
Taliani, M.R., **116**:301
Tanabe, N., **115**:219
Tanaka, K.A., **115**:79
Tanaka, Y., **116**:215
Tantry, U.S., **115**:89
Tanus-Santos, J.E., **115**:375
Tapon-Bretaudière, J., **116**:115
Taraskina, A.E., **115**:199
Tayebjee, M.H., **115**:205
Tchana-Sato, V., **116**:431
Tengiz, I., **116**:287
Thalamas, C., **116**:293
Thøgersen, A.M., **116**:249
Thrall, G., **115**:171
Tietjen, G.E., **115**:73
Tjeerdsma, G., **116**:279
Toba, K., **115**:219
Todolí, J., **115**:399
Tomaru, T., **115**:475
Tomasi, C., **116**:301
Tombuloglu, M., **115**:287
Tondi, F., **115**:405
Tóth, K., **116**:479
Trabetti, E., **116**:491
Tran, K., **115**:341
Tran, N.D., **115**:435
Trzeciak, M.C., **116**:483
Tsai, P.-J., **116**:145
Tsuda, Y., **116**:403
Tufano, A., **115**:439
Turcotte, I., **116**:41

Uchimura, T., **115**:319
Uchiyama, S., **115**:211
Umar, A., **115**:31
Unal, A., **116**:465
Uzuelli, J.A., **115**:375

Valent, P., **115**:59
Van den Besselaar, A.M.H.P., **115**:239
Van der Meer, F.J.M., **115**:387
Van Strijen, M.J.L., **115**:381
Van Veldhuisen, D.J., **116**:279
Vardy, M.D., **116**:1
Varricchione, N., **115**:439
Vavilova, T.V., **115**:199
Vaya, A., **115**:399, **116**:447
Veierød, M.B., **116**:313
Veres, K., **116**:139
Verheugt, F.W.A., **116**:279
Vermeer, H.J., **115**:381
Vernersson, E., **116**:15
Villa, P., **116**:447
Vlasin, M., **115**:427
Von Känel, R., **115**:175

Wada, H., **115**:53, **116**:307
Wada, Y., **115**:351
Wåhlander, K., **115**:9
Wajcman, H., **116**:115
Wakiyama, M., **115**:351
Wallen, H.N., **116**:509
Walli, A.K., **115**:39
Wang, W., **116**:335
Wang, X., **115**:95
Wang, Y., **115**:39, 319; **116**:385
Warshawsky, A.M., **116**:265
Waser, G., **116**:165
Watanabe, K., **115**:191, 351
Watson, C.C., **115**:461
Waxman, S., **116**:55
Weintraub, A., **116**:55
Weitz, J.I., **115**:427
Wells, P.S., **116**:101
Weltermann, A., **115**:59
Wijermans, P.W., **115**:381
Wiman, B., **116**:223
Winning, J., **116**:33
Wisloff, F., **115**:3
Wisløff, F., **115**:509
Wisser, H., **116**:171
Witsenburg, C.P.J., **115**:387
Witteveen, E., **115**:239

Wittmann, I., **116**:479
Wohlsein, P., **115**:229
Wu, F., **115**:341
Wu, Q., **115**:341
Wuillemin, W.A., **116**:165

Xiong, Y., **115**:211
Xu, L., **115**:95

Yamada, N., **115**:53; **116**:307
Yamaji, K., **115**:319
Yamakoshi, J., **115**:115
Yamamoto, H., **116**:357
Yamamoto, J., **115**:115, **116**:127, 393, 403
Yamashita, T., **115**:115; **116**:127, 393, 393, 403
Yamazaki, M., **115**:211
Yao, Q., **115**:417
Yasaka, M., **115**:455
Yatomi, Y., **115**:409
Ye, B., **115**:341
Yilmaz, M.B., **115**:25
Yilmaz, Y., **116**:465
Yoshida, E., **116**:255
Yoshimura, M., **115**:483
Ypma, P., **115**:381

Zgraggen, L., **115**:175
Zhao, Z., **115**:341
Zhou, W., **115**:435
Zhu, H., **116**:385
Zhu, J., **115**:503
Ziegler, S., **115**:59
Zion, M., **116**:1

Thrombosis Research (2005) **116**, 551–555

ELSEVIER

THROMBOSIS RESEARCH

intl.elsevierhealth.com/journals/thre

Keyword Index—Volumes 115-116 (2005)

20210A, **115**:351
Acetylsalicylic acid, **116**:139, 293
Acquired factor V inhibitor, **116**:87
Activated clotting time, **115**:9
Activated FXII, **115**:65
Activated partial thromboplastin time, **115**:9
Activated protein C, **115**:319
Acute coronary syndrome, **115**:475
Acute coronary syndromes, **115**:65
Acute leukemia, **115**:59
Acute myeloid leukaemia, **115**:109
Acute promyelocytic leukemia, **116**:109
Adenovirus, **116**:357
Adhesion molecules, **115**:19; **116**:91
Adiponectin, **115**:483
ADP, **115**:31, **116**:55
Adult plasma, **115**:135
Advanced glycation end products, **115**:319
Age, **115**:205
Age-dependent, **116**:127
Aggregation, **115**:89
Animal model, **115**:95; **116**:335
Annexin II, **115**:109
Anti coagulant therapy, **116**:279
Anti platelet therapy, **116**:279
Anticoagulant, **116**:41
Anticoagulant protein, **116**:421
Anticoagulants, **115**:245
Anticoagulation, **115**:45, **116**:121
Antigen, **116**:307
Antioxidant, **115**:417
Antiphospholipid antibodies, **115**:3
Antiphospholipid syndrome, **115**:405
Antiplatelet, **116**:293
Antiplatelet activity, **115**:495
Antiplatelet agent, **115**:309
Antithrombin, **115**:519, **116**:15, 171
Antithrombin deficiency, **116**:215
Antithrombotic, **115**:95, **116**:293
Antithrombotics, **115**:341
Anti-Xa activity, **116**:41
ApoE LDLR double knockout mouse, **116**:393
Aprotinin, **115**:327
Argatroban, **116**:121
Armagnac, **115**:31
Arterial thrombosis, **115**:95
ASA treatment, **116**:509
Aspirin, **115**:211, 367; **116**:465, 483
Aspirin resistance, **115**:25
Atherosclerosis, **115**:73, 482; **116**:393
Atorvastatin, **115**:263
ATRA, **116**:109
Atrial fibrillation, **116**:321
Autologous growth factor, **116**:87
Automation, **116**:171

B16F10 melanoma, **115**:123
Behçet's disease, **115**:159, 287, 399
Bleeding, **116**:109
Blood coagulation, **115**:175, 191
Blood coagulation disorders, **116**:15
Blood coagulation tests, **116**:9
Blood collection tube, **115**:239
Brazilin derivative, **115**:309
Bypass graft occlusion, **115**:39

C57BL/6 mice, **115**:115
Ca^{2+} mobilization, **115**:409
Calcium, **116**:241
Cangrelor, **115**:301
CAPD, **115**:19
Carboxypeptidase, **116**:499
Carboxypeptidase U, **116**:519
Cardiac thrombus, **115**:159
Cardiopulmonary bypass, **115**:327
Cardiopulmonary bypass surgery, **116**:33
Cardiovascular diseases, **116**:199
CD146, **115**:19
Cell cycle, **115**:219
Cell detachment, **116**:409
Cerebral cavernoma, **115**:405
Cerebral hemorrhage, **115**:367
Cerebral palsy, **116**:133
CHADS, **116**:321
Chemokine, **115**:277
Child, **116**:185
Children, **115**:185
Chloride-bicarbonate exchanger, **116**:67
Cholesterol, **115**:375
Cilostazol, **115**:211
Clopidogrel, **115**:89, 101; **116**:55, 293, 491

S0049-3848/$ - see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/S0049-3848(05)00387-7

Coagulation, **115**:159, 359, 519; **116**:171, 345, 421
Coagulation activation and fibrinolysis markers, **116**:33
Coagulation factor V, **116**:533
Coagulation factors, **116**:75
Coagulation FVII, **116**:313
Collagen, **115**:503
Computer modeling, **115**:327
Contact activation, **116**:33
Coronary artery disease (CAD), **115**:469, 483
Copenhagen rat, **115**:153
Coronary artery thrombosis, **116**:519
Coronary disease, **116**:525
Coronary heart disease, **115**:163
C-reactive protein (CRP), **115**:482
Critical stenosis, **115**:427
CRM-negative, **115**:191
CTL epitope, **116**:335
Curcumin, **115**:417
Cyclo-oxygenase 1 deficiency, **116**:483
Cyclosporin A, **115**:219
CYP2C9 polymorphism, **115**:199

3D microscopy, **116**:509
D-dimer, **115**:53, 271
D-dimer testing, **116**:165
D-Dimer PLUS, **115**:381
Deep vein thrombosis, **115**:351, **116**:215, 301
Deep venous thrombosis, **115**:381, **116**:165
Deficiency, **115**:191
Diabetes, **116**:465
Diagnostic strategy, **116**:165
Dialysis, **115**:185
Diet, **116**:313
Dipyridamole, **115**:435
Dipyridamole, **116**:293
Direct thrombin inhibitor, **116**:121
Disseminated intravascular coagulation (DIC), **116**:91
Disseminated intravascular coagulation, **115**:536
Diurnal variation, **115**:205
Dog, **115**:229
DVT, **115**:53; **116**:307

Ecarin clotting time, **115**:9
Endocarditis, **116**:145
Endothelial cell damage, **115**:219
Endothelial cell, **115**:417
Endothelial cells, **116**:233, 409
Endothelial damage, **116**:181
Endothelial dysfunction, **116**:181
Endothelial function, **116**:207
Endothelial nitric oxide synthase (eNOS), **115**:375
Endothelial nitric oxide synthase, **116**:287
Endothelial protein C receptor, **115**:417
Endothelium, **115**:19, 435; **116**:199
Eptifibatide, **115**:79
E-selectin, **116**:181
Estrogen, **115**:359; **116**:1
Ethnicity, **115**:205
Exercise, **115**:205
Experimental model, **115**:527
Expression, **116**:75
Expression study, **115**:191
Extracellular matrix, **115**:205

Factor FVII deficiency, **116**:115
Factor II, **116**:133
factor V Leiden, **115**:351
Factor V leiden, **116**:133
Factor VIII, **115**:387, **116**:335
Factor Xa, **115**:123
Factor XI, **115**:441
Factor XII, **115**:191
Fibrates, **115**:293
Fibrin degradation products, **115**:229
Fibrin degradation products by granulocyte elastase, **115**:53
Fibrin degradation, **115**:143
Fibrin fibrinogen degradation products, **115**:381
Fibrin gel permeability, **116**:509
Fibrinogen, **115**:39, 293; **116**:145, 171, 241
Fibrinogen consumption, **115**:427
Fibrinogen degradation, **115**:143
Fibrinolusis, **115**:359
Fibrinolysis, **115**:109, 327, 341; **116**:207, 265, 345
Fibrinolytic enzyme, **115**:143
Fibroblasts, **116**:357
Fish consumption, **115**:163
Flaveria bidentis, **115**:495
Flow cytometry, **115**:263, **116**:241
Framingham, **116**:321
Function, **116**:465
FV Leiden mutation, **115**:519

Gastrointestinal haemorrhage, **116**:185
Gender, **115**:205
Gene analysis, **115**:351
Gene mutation, **116**:115
Gene polymorphism, **116**:287
Gene therapy, **116**:335
Global assay, **116**:345
Global fibrinolytic capacity, **115**:185
Global haemostatic tests, **116**:15
Glycoprotein IIb/IIIa, **115**:263, 503; **116**:145
Glycoproteins, **115**:245
GPVI, **115**:409
Graft occlusion, **115**:25

H. pylori infection, **116**:471
Haemangiosarcoma, **115**:229
Haemostasis, **115**:229; **116**:185
Healthy volunteers, **115**:31
Heart failure, **116**:181, 279
HELLP syndrome, **115**:387
Hematocrit, **115**:175
Hemodynamics, **116**:431
Hemophilia, **115**:441
Hemophilia A, **116**:335
Hemorheology, **115**:399
Hemorrhagic complication, **115**:455
Hemostasis, **115**:95, 367; **116**:1
Heparin, **115**:45, 153, 301, 475
Heparin cofactor II, **116**:357
Heparin neutralization, **115**:509
Heparin-induced thrombocytopenia, **115**:475; **116**:121
Heparin-mediated extracorporeal low-density lipoprotein precipitation, **115**:39
Hepatic sequestration, **115**:79
High sensitive C-reactive protein, **116**:249
High-density lipoprotein cholesterol (HDL-C), **115**:483
HL-60 cell line, **116**:533
Human neutrophil elastase, **116**:533

Human placenta protein, **116**:421
Human plasma, **116**:157
Human umbilical vein endothelial cells, **115**:219
Hypercoagulability, **115**:527
Hyperlipidemia, **115**:263
Hypertension, **115**:277, 359

IL-6, **115**:393
Impaired renal function, **116**:41
Infarction, **115**:73
Inflammation, **115**:417; **116**:533
In-frame deletion, **116**:215
Inherited bleeding disorder, **116**:115
Inhibitor, **115**:503
Inhibitors, **116**:525
INR, **115**:239
INR (international normalized ratio), **115**:131
Insulin resistance, **116**:207
Intensive care, **116**:15
Interleukin-6, **116**:357
Interobserver reliability, **116**:101
Intima-media thickness (IMT), **115**:482
Intracellular degradation, **116**:215
Intracellular pH, **116**:67
Intrauterine growth restriction, **115**:387
Iron deprivation, **116**:255
Iron overload, **116**:157
i-STAT System Portable Clinical Analyser, **115**:131

Laser-induced thrombosis, **115**:115
LDL oxidation, **116**:157
Leukocyte, **116**:307
Lewis rat, **115**:153
Lipid peroxidation, **115**:319
Lipoprotein (a), **115**:39
Liver diseases, **116**:185
Low molecular weight heparin, **115**:45, 509; **116**:41
Lupus anticoagulant assays, **115**:509
Lymphocytes, **116**:199
Lysine, **116**:499

Magnesium, **115**:239
Matrix metalloproteinases, **115**:205
Medical patients, **116**:365
Melagatran, **115**:135
Mental stress test, **116**:25
Metalloproteases, **115**:143
Microparticles, **116**:409
Mitomycin C, **115**:219
Monitoring, **115**:131
Monoclonal antibodies, **115**:245
Monocytes, **116**:471
Mortality, **116**:15
Mouse, **115**:95
mRNA, **116**:307
mRNA binding protein, **116**:255
mRNA stability, **116**:255
MTHFR, **116**:133
Multiple organ dysfunction syndrome (MODS), **116**:91
Murine factor VII, **116**:75
Mutation, **115**:191
Myocardial infarction, **116**:139, 223, 431
Myocardial ischemia, **116**:33

n−3, **116**:393
n−6, **116**:393
Nephrotic syndrome, **115**:19
Neutrophil, **116**:91
Nifedipine, **115**:277
Nitrate, **115**:375
Nitric oxide, **115**:375; **116**:403
Nitrite, **115**:375
Normalized screening/confirm ratio, **115**:509
Nucleotide substitution, **116**:215

Obesity, **116**:41
Octreotide, **116**:185
Oral anticoagulants, **115**:131, 199
Oral direct thrombin inhibitor, **115**:135
Oral direct thrombin inhibitors, **115**:9

P2 receptor, **115**:301
PAI-1, **115**:341; **116**:127, 223, 255
PAI-1 inhibitor, **115**:341
Partial thromboplastin time, **116**:171
Percutaneous coronary intervention (PCI), **115**:469
Percutaneous coronary intervention, **115**:475
Peripheral arterial disease, **115**:39
PFA-100, **116**:139
PFA-100 testing, **116**:483
Phage display, **116**:385
Pharmacogenetics, **115**:199
Pharmacokinetics, **115**:45
Phosphatidylserine, **115**:263
Phospholipase A_2, **115**:309
Physical examination, **116**:101
Plasma kallikrein inhibitor, **116**:403
Plasma thrombosis, **115**:73
Plasma volume, **115**:175
Plasminogen activator inhibitor-1, **116**:233
Plasminogen activator inhibitor-2, **116**:471
Plasminogen, **115**:109; **116**:499
Platelet, **115**:89, 409, 503; **116**:127, 145, 385, 465, 483
Platelet activation, **115**:211, 263; **116**:377
Platelet adhesion, **116**:377
Platelet aggregation, **115**:31, 309, 495, 503; **116**:241
Platelet aggregation inhibitors, **115**:301
Platelet function, **115**:115; **116**:491
Platelet membranes neutralization, **116**:421
Platelet reactivity, **115**:115; **116**:25
Platelets, **115**:101, 245, 301, 367, 536; **116**:55, 67, 139, 199, 233, 241, 403, 499, 525
Platelets Thrombin, **115**:441
Pneumatic tourniquet (tourniquet), **115**:271
Polycystic ovary syndrome, **116**:207
Polymerisation, **115**:293
Polymorphism, **116**:491
Polymorphisms, **115**:375; **116**:313
Polyphenols, **115**:31
Polyunsaturated fatty acid, **116**:393
Polyunsaturated fatty acids, **115**:163
Post-transcriptional regulation, **116**:255
Potentiation of platelet collagen activation, **116**:51

PP27, **116**:421
Prednisolone, **115**:219
Pre-eclampsia, **115**:387
Preeclampsia, **116**:51, 377
Pregnancy, **115**:293, 405, 461
Pregnancy related hypertension, **115**:387
Pregnancy-induced hypertension, **116**:377
Premature coronary artery disease, **116**:287
Pretest probability, **116**:101
Proanthocyanidin, **115**:115
Procoagulant effect, **116**:421
Procoagulant markers, **115**:277
Proexosite I, **115**:123
Prognostic factors, **115**:59
Prokaryotic expression, **116**:385
Promoter polymorphisms, **115**:393
Prophylaxis, **116**:365
Prostacyclin, **115**:367
Protein C, **115**:519; **116**:15
Protein kinase G inhibitor, **115**:435
Protein S, **115**:519
Prothombin fragment (F1.2), **115**:469
Prothrombin complex concentrate, **115**:455
Prothrombin time, **115**:9, 239; **116**:171
Prothrombinase complex, **115**:123; **116**:533
P-selectin, **115**:263; **116**:241, 377
Psychological stress, **115**:175
PT (prothrombin time), **115**:131
Pulmonary arterial aneurysms, **115**:159
Pulmonary embolism, **115**:381; **116**:101, 301
Pulmonary thromboembolism (PTE), **115**:271

Raloxifene, **116**:1
Randomized controlled clinical trial, **115**:31
Randomized trial, **116**:279
Rat, **115**:527
Reactive oxygen species, **115**:319
Recombinant factor VIIa (rFVIIa), **116**:185
Remnant-like particles, **115**:211
Resonance thrombography, **115**:229
Risk factor, **116**:127
Risk factors, **116**:365
Risk marker, **116**:223
rt-PA, **116**:519

Saphenous vein grafts, **115**:25
Sepsis, **115**:536; **116**:91
SERMs—Selective Estrogen Receptor Modulators, **116**:1
SF, **115**:53
Shark cartilage extract, **115**:143
Shear stress, **115**:211
Shear-stress, **115**:115
Sialic acid, **115**:293
Single chain Fv fragment, **116**:385
Soluble E-selectin, **116**:321
Specimen collection, **116**:249
Sphingosine 1-phosphate, **115**:409
Sphingosine kinase, **115**:409
Spirits, **115**:31
Spontaneous thrombolysis, **116**:127
STA Liatest, **116**:165
Stability, **116**:249
Stable angina, **115**:65; **116**:25
Staphylococcus aureus, **116**:145
Stasis, **115**:527
Statins, **115**:469
Stents, **115**:101, 245
Streptokinase, **116**:139
Streptokinase-induced arterial patency, **115**:427
Stroke risk stratification, **116**:321
Stroke, **115**:393
Structure and function of antithrombin, **115**:351
Sulphated flavonoids, **115**:495
Superoxide anions, **116**:157
Survival, **115**:59
Syndrome X, **116**:25
Systemic inflammatory response syndrome (SIRS), **116**:91

TAFI, **116**:265
TAFI and thrombosis, **115**:287
TAFIa, **116**:519
Tamoxifen, **116**:1
TF, **116**:307
Thiols, **116**:157
Thrombelastography, **115**:461
Thrombin, **115**:123; **116**:67, 525
Thrombin clotting time, **115**:9
Thrombin formation, **116**:33
Thrombin generation, **116**:483
Thrombocytopathy, **116**:483
Thrombocytopenia, **115**:79
Thromboembolism, **115**:3
Thrombogenesis, **116**:293
Thrombolysis, **115**:341; **116**:139, 403, 519
Thrombomodulin, **115**:417; **116**:181, 249, 471
Thrombophilia, **115**:461, 519; **116**:109, 133, 301
Thromboplastin antecedent, **115**:441
Thromboplastin, **115**:239; **116**:421
Thrombopoietin, **116**:51
Thrombosis, **115**:39, 101, 399; **116**:55, 121, 127, 199, 265, 403, 431, 525
Thrombospondin-1, **116**:533
Thromboxane, **115**:367
Thromboxane A_2, **115**:309
Thrombus, **116**:431
Tirofiban, **116**:55
Tissue factor, **116**:75, 233, 471
Tissue factor (TF), **115**:469; **116**:409
Tissue factor pathway inhibitor (TFPI), **115**:469; **116**:409
Tissue inhibitor of metalloproteinase, **115**:205
Tissue plasminogen activator, **115**:109, 435
Tissue-type plasminogen activator, **116**:357
TLR, **115**:536
TNF-α, **115**:393, 417
Total antioxidant capacity, **116**:157
Total knee arthroplasty (TKA), **115**:271
tPA, **116**:223
tPA-PAI-1 complex, **116**:249
Transforming growth factor beta-1, **116**:233

Triglycerides, **115**:65
Type 2 diabetes mellitus, **115**:277

Umbilical cord plasma, **115**:135
Unstable angina, **116**:25
Uteroplacental insufficiency, **115**:387

Vascular smooth muscle cells, **116**:357
Vasodilation, **116**:207
Veno-occlusive disease, **116**:233
Venous thromboembolism, **115**:59; **116**:301, 365
Venous thrombosis, **115**:527
Vessel injury, **115**:527
Vitamin K antagonists, **115**:131
Vodka, **115**:31
Von Willebrand factor, **116**:181, 321
Von Willebrands factor, **116**:249
VWF, **116**:385

Warfarin, **115**:3, 455; **116**:279
Warfarin therapy, **115**:199
Women, **115**:359

Ximelagatran, **115**:9, 135